What the board approved
At its meeting on August 5, 2026, Aurobindo Pharma's board approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The statutory auditors, Deloitte Haskins & Sells, issued an unmodified conclusion on the limited review.
Separately, the board approved a proposal to file a Scheme of Amalgamation with the NCLT, Hyderabad, to merge two wholly owned step-down subsidiaries, Eugia Steriles Private Limited and Eugia SEZ Private Limited, into Eugia Pharma Specialities Limited, another wholly owned subsidiary — an internal group reorganisation among entities the company already owns.
A quarter shaped by the Lannett acquisition
The defining feature of the quarter sits in the notes: on June 29, 2026 the company, through its subsidiary Aurobindo Pharma USA, Inc., completed the acquisition of 100% of Lannett Company LLC and its subsidiaries. Because Lannett was consolidated from that date, the filing states plainly that "the results for the quarter ended June 30, 2026, are not comparable to the earlier periods presented."
The consolidated numbers reflect this scale-up versus the year-ago quarter, while the standalone (parent-only) figures — which the acquisition does not touch — moved more modestly. The company also recorded acquisition and related costs as an exceptional item in the consolidated results, and a net loss on derecognition of a lease receivable within other expenses at its US subsidiary.
Deals during and after the quarter
The filing records further corporate activity around the period. During the quarter the company took a 26% stake in Swarnaakshu Solar Power Private Limited, making it an associate, and incorporated new subsidiaries in France and Indonesia. It also transferred its domestic branded generic formulations business to wholly owned subsidiary Auropharm Limited with effect from April 1, 2026.
After quarter-end, on July 23, 2026, subsidiary Apitoria Pharma approved acquiring an 80% interest in the A1 Biochem Group at an enterprise value of USD 17.0 million — a transaction the company expects to complete within 90–120 days. The quarter also carried the effect of a buyback of shares approved in April 2026.